# Probenecid (PB) to Treat Hereditary Nephrogenic Diabetes Insipidus (NDI), ADPKD Treated With Tolvaptan, and Severely Polyuric Patients With Previous Lithium Administration

> **NCT05190744** · PHASE2 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 36 (actual)

## Conditions studied

- Autosomal Dominant Polycystic Kidney Disease
- Nephrogenic Diabetes Insipidus
- Acquired Nephrogenic Diabetes Insipidus
- Congenital Nephrogenic Diabetes Insipidus

## Interventions

- **DRUG:** PB

## Key facts

- **NCT ID:** NCT05190744
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-01
- **Primary completion:** 2025-12-08
- **Final completion:** 2025-12-08
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2026-01-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05190744

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05190744, "Probenecid (PB) to Treat Hereditary Nephrogenic Diabetes Insipidus (NDI), ADPKD Treated With Tolvaptan, and Severely Polyuric Patients With Previous Lithium Administration". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05190744. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*